ARCHIVES

Funding Exceptions, Skipovers, While Limited At NCI, Become Crucial Issues; NCAB To Be Brief On Details

This article is from The Cancer Letter archive.

Vol. 09 No. 01 | January 7, 1983

Download PDF Visit The Full Archive

Related Articles

Sharfstein To Leave FDA

January 7, 2011

Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles With SEC Over Shorting Dendreon Stock

December 17, 2013

NCAB Recommends Withdrawal Of CRCC Comprehensive Status

February 13, 1981

In Brief: Last Bit of Nonsense By Weinberger; Magnuson May Write NCI Positions Into HEW Money Bill

July 18, 1975

FDA Likely To Change Procedures For Patient Interaction, Official Says

November 10, 1995

Lame-Duck Session Required To Complete HHS Funding Bill; Nobel Laureates For Gore.

November 10, 2000